News

Category

SynDermix Announces Interim Changes to Leadership

Delegate of the Board and Chief Executive Officer of SynDermix AG, Mr. Dieter Hemmer, on medical leave of absence; Dr. ...

Read More

Update on the Clinical Trial of the SDX-3101 Medical Device

SynDermix AG announced temporary postponement of initiation of the SDX-3101 clinical trial on chronic rhinosinusitis without nasal polyps due to ...

Read More

First Site Initiation Visit (SIV) Completed for the Clinical Trial of SDX-3101 in Austria

SynDermix AG is pleased to announce the successful completion of the first SIV for the clinical trial of SDX-3101, in ...

Read More

Collaboration with King’s College London on the Formulation Development of SDX-21

SynDermix AG is proud to announce its collaboration with King’s College London for the development of its Nitric Oxide technology. ...

Read More

AGM 2019: Re-election of Chairman and Board of Directors

Shareholders approve all proposals put forward by the Board of Directors and re-elect the Chairman and Directors to the board ...

Read More

SynDermix to Sell Majority Stake of SDX-Cosmetics

SynDermix announces the sale of a majority stake of SDX Cosmetics – formerly a fully owned subsidiary of SynDermix AG. ...

Read More

SynDermix Announces Changes to the Executive Team

The Board of SynDermix announces changes in the management and executive team.   ZURICH, SWITZERLAND – 1 April, 2019 The ...

Read More

Share Capital Increased

The Board of Directors announces a successful increase of share capital: A total of CHF 1 000 000 in loans ...

Read More

CHF 10 Million Investment

The Board of SynDermix is pleased to announce the closure of a new investment of CHF 10 million in the ...

Read More

SDX-3103 Kick-Off Meeting, Biel

SynDermix announces the successful kick-off meeting of the project SDX-3103, a proprietary medical device for the treatment and prevention of ...

Read More